Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q1 FY2023 Earnings Presentation
27 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Aug 10, 2022
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q1FY23
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q1FY23 Aug 2022
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Executive Director & CEO Message
Executive Director & CEO Message The domestic economy is witnessing revival in consumption and recovery in the services sector, which has allayed any recession related speculation. Over the next few years, our focus will be on diversifying into other speciality chemical products and increase the sha
Slide 5: Financial Overview
Financial Overview 5
Slide 6: Key Financial Summary
Key Financial Summary Financial Summary Q1FY23 Q4FY22 Q1FY22 (INR Cr) Total Income 570 579 524 Gross Profit 176 151 189 EBITDA 61 50 116 PAT 35 28 67 6 All Profits and Total Income include Other Income
Slide 7: Quarterly Financial Performance
Quarterly Financial Performance Quarterly Revenues & Margins* Quarterly Segmental EBIT % 700 40% 25% 36% 23% 600 579 570 35% 524 20% 30% 500 31% 16% 25% 15% 400 22% 26% 20% 12% 13% 10% 300 15% 11% 200 9% 5% 5% 13% 10% 100 5% 0% 6% 5% Q1FY22 Q4FY22 Q1FY23 0 0% -2% Q1FY22 Q4FY22 Q1FY23 -5% Pharmaceuti
Slide 8: Geographical Segmental Breakup – Annual & Quarter
Geographical Segmental Breakup – Annual & Quarter Annually Quarterly In INR crs In INR crs 1800 1638 1600 1400 1355 1250 1200 1038 1000 38% 34% 31% 800 25% 633 647 645 613 600 36% 546 403 29% 394 435 400 350 31% 16% 162 178 200 83 0 FY18 FY19 FY20 FY21 FY22 Q1FY23 Q4FY22 Q1FY22 Domestic Export 8 *FY
Slide 9: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual 2,216 50% 1,911 1,991 45% 2,000 38% 44% 45% 40% 1,696 31% 35% 1,500 30% 30% 25% 31% 29% 990 25% 1,000 20% 14% 22% 19% 15% 13% 13% 500 10% 7% 5% 3% - 0% FY18 FY19 FY20 FY21 FY22 Total Income Gross Profits % EBITDA % PAT % Segmental
Slide 10: Financial Summary – Statement of Profit and Losses
Financial Summary – Statement of Profit and Losses P&L (INR Crs) FY18 FY19 FY20 FY21 FY22 Q1FY23 Q4FY22 Q1FY22 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 565.0 572.5 518.5 Other Income 6.3 10.4 16 24.3 32.0 5.2 6.9 5.7 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 570.2 579.4 524.2 Gross Pr
Slide 11: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY18 FY19 FY20 FY21 FY22 Shareholder's Funds 215.7 474.3 813.5 1260.4 1390.3 Debt 421.9 284 56 0 0 Other Long Term Liabilities 33.6 20.8 79.7 59.1 56.6 Other Current Liabilities 180.9 162.8 220.6 290.6 513.4 Equity & Liabilities 852.1 941.9 1
Slide 12: Shareholding Information
Shareholding Information Stock Data (As on 9th Aug, 2022) Shareholding Pattern (%) Market Capitalization (₹) 2,087 Crore 53.8% 51.2% Face Value(₹) 10 43.7% 43.7% Share Price (₹) 355.6 EPS TTM (₹) 22.8 52-Week High (₹) 670.0 5.1% 2.5% 52-Week Low (₹) 295.1 Promoter Institutional Non-institutional Sym
Slide 13: Product wise Segmentation – Quarterly
Product wise Segmentation – Quarterly Q1FY23 Q4FY22 Q1FY22 565 572 519 113 112 61 20% 20% 12% 277 152 280 50% 48% 306 183 29% 172 32% 59% 30% Chemicals Ibuprofen Other API’s 13 All figures in INR crs unless stated
Slide 14: Ratios
Ratios Ratios FY22 FY21 Debt-Equity Ratio (in times) 0.03 0.00 Return on Equity (%) 12.50 42.87 Return on Capital Employed (%) 16.12 43.49 Return on Investment (%) 5.19 5.86 14
Slide 15: Annexure
Annexure 15
Slide 16: Key Highlights
Key Highlights Team size of 2,300+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 17: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 18: Experienced Independent Directors
Experienced Independent Directors • Mr. Rajender has very distinguished career of four • Mr. Harpal has had over 35 year's experience of banking decades. and financial services. • He had held top and significant decision-making • Most recently he was General Manager of Punjab positions in Banks, Fin
Slide 19: Our Journey
Our Journey Unit-08 & Unit- Unit-06 for Conversion of 10* for Multi Pantoprazole Unit-2 as Dedicated USFDA, EIR for 2022 Products 2020 (Dedicated) 2018 facility for Ibuprofen 2016 2013 Ibuprofen Commenced Unit-07 Metformin Unit-04 Metformin Received EUGMP 2021 2019 2017 Unit-03 for new 2015 commerci
Slide 20: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 21: Product Segmentation
Product Segmentation 21
Slide 22: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added 8 new products in Product portfolio that producer of Metf
Slide 23: Pharmaceuticals Product Portfolio – Commercialized & Pipeline
Pharmaceuticals Product Portfolio – Commercialized & Pipeline API - Commercialized API – Pipeline/ Validation Ibuprofen Irbesartan Ibuprofen Lysinate Valsartan Ibuprofen Sodium Vildagliptin Dex-Ibuprofen Sitagliptin M Phosphate Metformin HCL Quetiapine Fumarate Clopidogrel Bisulphate (Form II) Allop
Slide 24: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 25: Manufacturing Facility spread across over 111 acres with GMP approved guidelines
Manufacturing Facility spread across over 111 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 26: Our Core Sustainability Pillars
Our Core Sustainability Pillars • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum utilization of resources and • Primary healthcare including s
Slide 27: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Q1 FY2023 Earnings Presentation on 6ix